PEARL: A Non-interventional Study of Real-World Alirocumab Use in German Clinical Practice
Abstract Background Several lipid guidelines recommend that proprotein convertase subtilisin/kexin type 9 inhibitors should be considered for patients with atherosclerotic cardiovascular disease who are inadequately treated with maximally tolerated lipid-lowering treatment. Objectives The PEARL stud...
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Adis, Springer Healthcare
2019-07-01
|
| Series: | Drugs - Real World Outcomes |
| Online Access: | http://link.springer.com/article/10.1007/s40801-019-0158-0 |